Ginkgo Bioworks Holdings, Inc. $DNA Shares Sold by Baillie Gifford & Co.

Key Points

• Baillie Gifford cut its position in Ginkgo Bioworks by 26.1%, selling 843,605 shares and now holds 2,391,649 shares (~3.95%); institutional investors collectively own 78.63% of DNA while several funds simultaneously added or initiated positions.
• Analyst sentiment is negative: MarketBeat shows a consensus "Reduce" rating with an average target of $8.50, even as Ginkgo reported an EPS beat (‑$1.42 vs. ‑$1.80) but missed revenue; the stock trades around $6.69 and the company remains unprofitable with a market cap near $414M.
• Insiders sold a total of 510,458 shares (~$3.34M) in the last quarter—including sizable sales by Reshma Shetty and CEO Jason Kelly to cover tax withholding—leaving insiders owning 9.72% of the company.

Baillie Gifford & Co. lessened its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 26.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,391,649 shares of the company's stock after selling 843,605 shares during the period. Baillie Gifford & Co. owned about 3.95% of Ginkgo Bioworks worth $19,875,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DNA. Millennium Management LLC grew its holdings in Ginkgo Bioworks by 113.1% during the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock worth $8,137,000 after acquiring an additional 757,535 shares in the last quarter. Erste Asset Management GmbH grew its holdings in Ginkgo Bioworks by 10.0% during the 3rd quarter. Erste Asset Management GmbH now owns 2,200,000 shares of the company's stock worth $32,076,000 after acquiring an additional 200,000 shares in the last quarter. Allianz Asset Management GmbH acquired a new position in Ginkgo Bioworks during the 3rd quarter worth approximately $2,802,000. Goldman Sachs Group Inc. grew its holdings in Ginkgo Bioworks by 25.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock worth $3,915,000 after acquiring an additional 139,126 shares in the last quarter. Finally, Caxton Associates LLP acquired a new position in Ginkgo Bioworks during the 3rd quarter worth approximately $1,889,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on DNA shares. Wall Street Zen upgraded shares of Ginkgo Bioworks from a "sell" rating to a "hold" rating in a report on Saturday. BTIG Research lowered their price target on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a "sell" rating for the company in a report on Thursday, March 12th. TD Cowen lowered their target price on shares of Ginkgo Bioworks from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, January 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Ginkgo Bioworks in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Ginkgo Bioworks has a consensus rating of "Reduce" and an average target price of $8.50.

Ginkgo Bioworks Trading Up 3.7%

Shares of Ginkgo Bioworks stock opened at $6.69 on Tuesday. The company has a fifty day simple moving average of $7.58 and a 200-day simple moving average of $9.45. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.37 and a 12-month high of $17.58. The stock has a market cap of $414.00 million, a price-to-earnings ratio of -1.18 and a beta of 1.56.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($1.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.38. Ginkgo Bioworks had a negative net margin of 183.81% and a negative return on equity of 52.82%. The business had revenue of $33.40 million during the quarter, compared to analysts' expectations of $37.57 million. On average, analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Reshma P. Shetty sold 124,727 shares of the company's stock in a transaction on Friday, April 10th. The shares were sold at an average price of $6.43, for a total value of $801,994.61. Following the completion of the transaction, the insider owned 436,422 shares in the company, valued at approximately $2,806,193.46. This represents a 22.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason R. Kelly sold 109,767 shares of the stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $6.40, for a total transaction of $702,508.80. Following the sale, the insider owned 316,483 shares of the company's stock, valued at approximately $2,025,491.20. This represents a 25.75% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 510,458 shares of company stock worth $3,342,467. Corporate insiders own 9.72% of the company's stock.

Ginkgo Bioworks Profile

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company's services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.